Cargando…

Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern

BACKGROUND: Liver metastasis is a poor prognostic factor for treatment of advanced cutaneous melanoma with either immunotherapy or targeted therapies. In this study we focused on NRAS mutated melanoma, a cohort with high unmet clinical need. METHODS: WT31 melanoma was repeatedly passaged over the li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dietsch, Bianca, Weller, Céline, Sticht, Carsten, de la Torre, Carolina, Kramer, Martin, Goerdt, Sergij, Géraud, Cyrill, Wohlfeil, Sebastian A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182637/ https://www.ncbi.nlm.nih.gov/pubmed/37179302 http://dx.doi.org/10.1186/s12885-023-10912-4

Ejemplares similares

Angiogenic and molecular diversity determine hepatic melanoma metastasis and response to anti-angiogenic treatment
por: Wohlfeil, Sebastian A., et al.
Publicado: (2022)

Lyve-1 deficiency enhances the hepatic immune microenvironment entailing altered susceptibility to melanoma liver metastasis
por: Jauch, Anna Sophia, et al.
Publicado: (2022)

Systemic Therapy of Non-Resectable Metastatic Melanoma
por: Orouji, Azadeh, et al.
Publicado: (2010)

NRAS mutant melanoma – undrugable?
por: Posch, Christian, et al.
Publicado: (2013)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Angiocrine Wnt signaling controls liver growth and metabolic maturation in mice
por: Leibing, Thomas, et al.
Publicado: (2018)

Playing POLO-like kinase in NRAS mutant melanoma
por: Chen, Hsin-Yi, et al.
Publicado: (2015)

NRAS-mutant melanoma: current challenges and future prospect
por: Muñoz-Couselo, Eva, et al.
Publicado: (2017)

Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma
por: Garcia-Alvarez, Alejandro, et al.
Publicado: (2021)

Deficiency for scavenger receptors Stabilin‐1 and Stabilin‐2 leads to age‐dependent renal and hepatic depositions of fasciclin domain proteins TGFBI and Periostin in mice
por: Leibing, Thomas, et al.
Publicado: (2023)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
por: Hirata, Amanda S., et al.
Publicado: (2021)

Efficacy of Targeted Radionuclide Therapy Using [(131)I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma
por: Akil, Hussein, et al.
Publicado: (2021)

Imbalanced Activation of Wnt-/β-Catenin-Signaling in Liver Endothelium Alters Normal Sinusoidal Differentiation
por: Koch, Philipp-Sebastian, et al.
Publicado: (2021)

Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma
por: Reyes-Uribe, Patricia, et al.
Publicado: (2018)

Variation of mutant allele frequency in NRAS Q61 mutated melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2017)

Long‐Term Response to Intermittent Binimetinib in Patients with NRAS‐Mutant Melanoma
por: Matter, Alexandra Valeska, et al.
Publicado: (2020)

UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma
por: Bowman, Robert L, et al.
Publicado: (2021)

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
por: Murphy, Brandon M., et al.
Publicado: (2022)

ALK expression favorably impacts the prognosis of NRAS-mutated metastatic melanomas
por: Osella-Abate, Simona, et al.
Publicado: (2018)

Pianp deficiency links GABA(B) receptor signaling and hippocampal and cerebellar neuronal cell composition to autism-like behavior
por: Winkler, Manuel, et al.
Publicado: (2019)

MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma
por: Vu, Ha Linh, et al.
Publicado: (2015)

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
por: Schuler, Martin, et al.
Publicado: (2022)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

Unique Cell Type-Specific Junctional Complexes in Vascular Endothelium of Human and Rat Liver Sinusoids
por: Géraud, Cyrill, et al.
Publicado: (2012)

Case report: Later onset of NRAS-mutant metastatic melanoma in a patient with a partially-excised giant congenital melanocytic nevus
por: Costa, Bruno Almeida, et al.
Publicado: (2022)

Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin
por: Xia, Yun, et al.
Publicado: (2016)

α-Mangostin, a Natural Agent, Enhances the Response of NRAS Mutant Melanoma to Retinoic Acid
por: Xia, Yun, et al.
Publicado: (2016)

The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma
por: Sanlorenzo, Martina, et al.
Publicado: (2018)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date
por: Boespflug, Amélie, et al.
Publicado: (2017)

Targeted treatment of advanced NRAS-mutated melanoma
por: Koelblinger, Peter, et al.
Publicado: (2017)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
por: Posch, C, et al.
Publicado: (2015)

Chromatin state profiling reveals PRC2 inhibition as a therapeutic target in NRAS–mutant melanoma
por: Terranova, Christopher J.
Publicado: (2021)

HSP70 Inhibition Blocks Adaptive Resistance and Synergizes with MEK Inhibition for the Treatment of NRAS-Mutant Melanoma
por: Parris, Joshua L.D., et al.
Publicado: (2021)

DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF
por: Gutierrez-Prat, Nuria, et al.
Publicado: (2022)

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer
por: Queralt, Bernardo, et al.
Publicado: (2016)

Human Chitinases and Chitinase-Like Proteins as Indicators for Inflammation and Cancer
por: Kzhyshkowska, Julia, et al.
Publicado: (2007)

ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver
por: Schmid, Christian David, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9h5u0u02avk988pat9tns11bfh